Feminizing Hormone Therapy

A comprehensive guide for prescribing and monitoring feminizing hormone therapy.

Hormonal Agents

A comprehensive overview of feminizing hormone therapy, including hormonal agents, formulations, and recommended doses.

The anti-androgens typically used at Sherbourne Health are spironolactone and cyproterone, with the former historically chosen preferentially as it was believed to have a superior safety profile. This practice has changed somewhat over time, as adequate anti-androgen effects and testosterone suppression into the female range have been shown to be attainable at lower doses of cyproterone (i.e., 12.5 mg daily) at which adverse effects are less likely. Thus the choice of anti-androgen should be made individually for each patient based on their medical history and preference regarding risk and side effect profiles.

If contraindications or intolerances exist for both spironolactone and cyproterone, GnRH analogs (leuprolide or “Lupron”) may be considered. Finasteride is a less effective anti-androgen and is generally not recommended, but may be considered for those who desire very mild anti-androgenic effects (dose range 1-5 mg daily).

Following orchiectomy (+/- vaginoplasty), most transfeminine patients will not require androgen suppression. The androgen-blocker can be stopped immediately after surgery or tapered over the course of 4-6 weeks or more depending on risk factors (e.g., in patients with hypertension or renal dysfunction on spironolactone consider monitored taper).

Anti-Androgen Formulations and Doses

Formulation
Starting Dose
Usual Dose

Maximum Dose

Spironolactone (oral)

50 mg daily – BID

100 mg BID

150 mg BID*

Cyproterone (oral)

2.5-5 mg daily (if compounding available, 12.5 mg (1/4 50 mg tab) q2d-daily

12.5 mg (1/4 50 mg tab) daily

Doses above 12.5 mg daily are rarely required but can be considered on a case-by-base basis


* Rarely required or used; maximal effect does not necessarily require maximal dosing. Use clinical judgment in selecting optimal individual dosing.

For help deciding which anti-androgen may be best for an individual patient, please refer to the following table comparing effects, side effects, and contraindications of spironolactone and cyproterone.

Estrogen acts directly on estrogen receptors to initiate feminization. Several forms and routes of estrogen have been used for feminization. At Sherbourne Health, the most common form used is oral 17-β estradiol (Estrace), which is now covered by the ODB program without an EAP request. While conjugated estrogens (e.g., Premarin) have historically been used due to their accessibility/affordability, they are no longer recommended.

There is a lack of consensus on the preferred timing of the initiation of estrogens in relation to an anti-androgen. Common approaches have included both the initiation of an anti-androgen (usually 1-3 months) prior to the addition of estrogen, or alternatively, the simultaneous introduction and subsequent titration of both components. The starting dose of estrogen can be maintained for 1-2 months, after which a dose increase can be considered barring any concerning effects. In patients over 50 years old who have been on estrogen for several years, doses may be reduced to those administered to post-menopausal cis women (e.g., starting/low dose topical formulations, i.e., 0.025 – 0.05 mg patch).

Estrogen Formulations and Doses

Formulation
Starting Dose
Usual Dose

Maximum Dose

Estradiol (oral)

1-2mg daily

4 mg daily or 2 mg bid

6 mg daily or 3 mg BID

Estradiol (transdermal, patch)

50 mcg daily/apply patches 2x/week

Variable*

200 mcg daily/apply patch 2x/week

Estradiol (transdermal, gel)

2.5 g daily (2 pumps, contains 150 mcg estradiol)

Variable*

6.25 g daily (5 pumps, contains 275 mcg estradiol), may be limited by surface area requirements for gel application

Estradiol valerate –
IM/SC (compounded)

3-4 mg weekly

3-5 mg weekly

7-8 mg weekly (rarely required)


* Usual doses vary significantly between individuals. Use starting doses and titrate up based on patient response. Maximum doses are not often needed. Use clinical judgment in selecting optimal individual dosing.

Keep in mind: If a patient is taking IM estrogen and wishes to self-inject, it is important to instruct them on the technique for safe injection and sharps disposal. A written step-by-step guide on self-injection for patients is available from Fenway Health.

With the exception of cyproterone, the use of progestins in transfeminine patients continues to be controversial.1 There have been anecdotal reports of improved breast and/or areolar development, mood, sleep, and libido with the use of progestins;2,3 however a clear impact has yet to be demonstrated. Common side effects include weight gain, edema and depression. Given the lack of clear benefit, and potential risks, progestins are not routinely recommended as part of a feminizing hormone regimen. However, should patients request progestins, a trial may be considered following a frank discussion of expectations and risks. Further information can be found in the full Guidelines and Checklist for Patient Review: Initiation of Progestin Therapy.

Expected Effects of Combined Therapy

Keep in mind: hormone therapy results in both reversible and irreversible feminization.

The degree and rate of physical effects are largely dependent on patient-specific factors such as age, genetics, body habitus and lifestyle, and to some extent the dose and route used (selected in accordance with a patient’s specific goals and risk profile). Physical changes related to androgen blockade and estrogen may take months to appear and are generally considered to be complete after 2-3 years on hormone therapy.

Breast growth is an aspect of feminization to which many transfeminine patients often assign great importance. The degree of breast development is dependent on many factors, but most transfeminine patients experience modest breast development (average cup size < A, or developmental Tanner stage 2 to 3).4 In early studies, neither type nor dosage of estrogen was shown to affect final breast size, and no relationship between serum estradiol levels and breast development was found.4,5

Feminizing therapy does not affect the pitch of the voice in transfeminine patients. Some patients may obtain benefit from voice therapy with a qualified and supportive speech and language therapist who can work with the patient to modify their vocal characteristics. There are also a variety of surgical techniques (not covered by OHIP) that have been utilized to feminize the voice through alteration of the vocal cords.

Effects and Expected Time Course

Hover over the diagram to view information on the reversibility, expected onset and maximum effects of physical changes.1

Physical Effects
Onset
Max. Effect

Reversiblity

Softening of skin/decreased oiliness

3-6 months

Unknown

Reversible

Thinned or slowed growth of body/facial hair

6-12 months

> 3 years

Reversible

Scalp hair loss (loss stops, no regrowth)

1-3 months

Variable

Reversible

Decreased muscle mass/strength

3-6 months

1-2 years

Reversible

Breast growth

3-6 months

1-2 years

Irreversible

Body fat redistribution

3-6 months

2-3 years

Variable

Decreased testicular volume

3-6 months

2-3 years

Variable

Decreased libido

1-3 months

3-6 months

Variable

Decreased spontaneous erections

1-3 months

3-6 months

Variable

Decreased sperm production

Unknown

> 3 years

Variable

Reduced erectile function

Unknown

> 3 years

Variable

Feminizing Hormone Therapy Effects
Skin Changes Skin Changes Hair Changes Hair Changes Decreased Muscle Mass and Strength Decreased Muscle Mass and Strength Decreased Muscle Mass and Strength Breast Growth Breast Growth Body Fat Redistribution Body Fat Redistribution Body Fat Redistribution Reproductive and Sexual Health Reproductive and Sexual Health

Skin Changes

Skin becomes softer and less oily; acne may decrease

Reversibility: Reversible
Expected Onset: 3 - 6 months
Expected Max. Effect: Unknown

Skin Changes

Skin becomes softer and less oily; acne may decrease

Reversibility: Reversible
Expected Onset: 3 - 6 months
Expected Max. Effect: Unknown

Hair Changes

Thinned or slowed growth of facial and body hair. Note: the complete removal of facial and body hair requires electrolysis, laser treatment, or both.

Reversibility: Reversible
Expected Onset: 6 - 12 months
Expected Max. Effect: >3 years

Scalp hair loss stops progressing, no regrowth.

Reversibility: Reversible
Expected Onset: 1 - 3 months
Expected Max. Effect: Variable

Hair Changes

Thinned or slowed growth of facial and body hair. Note: the complete removal of facial and body hair requires electrolysis, laser treatment, or both.

Reversibility: Reversible
Expected Onset: 6 - 12 months
Expected Max. Effect: >3 years

Scalp hair loss stops progressing, no regrowth.

Reversibility: Reversible
Expected Onset: 1 - 3 months
Expected Max. Effect: Variable

Decreased Muscle Mass and Strength

Reduction in muscle mass and strength; significantly dependent on the amount of exercise.

Reversibility: Reversible
Expected Onset: 3–6 months
Expected Max. Effect: 1–2 years

Decreased Muscle Mass and Strength

Reduction in muscle mass and strength; significantly dependent on the amount of exercise.

Reversibility: Reversible
Expected Onset: 3–6 months
Expected Max. Effect: 1–2 years

Decreased Muscle Mass and Strength

Reduction in muscle mass and strength; significantly dependent on the amount of exercise.

Reversibility: Reversible
Expected Onset: 3–6 months
Expected Max. Effect: 1–2 years

Breast Growth

Reversibility: Irreversible
Expected Onset: 3 - 6 months
Expected Max. Effect: 1 - 2 years

Breast Growth

Reversibility: Irreversible
Expected Onset: 3 - 6 months
Expected Max. Effect: 1 - 2 years

Body Fat Redistribution

Fat redistributes from abdomen and mid-section regions to the buttocks, hips and thighs.

Reversibility: Reversible/Variable
Expected Onset: 3 - 6 months
Expected Max. Effect: 2 - 3 years

Body Fat Redistribution

Fat redistributes from abdomen and mid-section regions to the buttocks, hips and thighs.

Reversibility: Reversible/Variable
Expected Onset: 3 - 6 months
Expected Max. Effect: 2 - 3 years

Body Fat Redistribution

Fat redistributes from abdomen and mid-section regions to the buttocks, hips and thighs.

Reversibility: Reversible/Variable
Expected Onset: 3 - 6 months
Expected Max. Effect: 2 - 3 years

Reproductive and Sexual Health

The reversibility of the following effects is variable. Decreased sperm production (infertility) as well as reduced erectile function may also occur.

Decreased Testicular Volume
Expected Onset: 3–6 months
Expected Max. Effect: 2–3 years

Decreased Libido
Expected Onset: 1–3 months
Expected Max. Effect: 3–6 months

Decreased Spontaneous Erections
Expected Onset: 1–3 months
Expected Max. Effect: 3–6 months

Reproductive and Sexual Health

The reversibility of the following effects is variable. Decreased sperm production (infertility) as well as reduced erectile function may also occur.

Decreased Testicular Volume
Expected Onset: 3–6 months
Expected Max. Effect: 2–3 years

Decreased Libido
Expected Onset: 1–3 months
Expected Max. Effect: 3–6 months

Decreased Spontaneous Erections
Expected Onset: 1–3 months
Expected Max. Effect: 3–6 months

Risk Mitigation

Pre-existing medical conditions and risk factors may impart increased risks with estrogen administration and should be considered in order to enable individualized discussions with patients regarding their unique risks and benefits of treatment. Available measures to reduce associated risks should be considered and discussed with patients and, if possible, undertaken prior to or concurrently with the initiation of hormone therapy.

Contraindications

  • Unstable ischemic cardiovascular disease
  • Estrogen-dependent cancer
  • End stage chronic liver disease
  • Psychiatric conditions which limit the ability to provide informed consent
  • Hypersensitivity to one of the components of the formulation

Harm Reduction

In many cases, denying access to hormones can do much more harm than the possible risk of treatment. With an informed consent approach (support, information, education and consent) many providers will initiate hormones with individuals with higher risk profiles when it increases their quality of life/chance survival greatly.

Neurologic

Precautions in red impart moderate to high risk of an adverse outcome without risk mitigation. For more information on seizure disorders and anticonvulsant therapy, consult the Guidelines.

Risk Factors
How to Minimize Risks

Cerebrovascular disease

Consider referral to neurology, ensure optimal medical management (including prophylactic anti-platelet agent(s) if indicated per current national guidelines) and risk factor optimization, use transdermal route of administration +/- lower dose

Consider referral to neurology, consider daily migraine prophylaxis, ensure all other cerebrovascular risk factors are optimized, consider transdermal route of administration, consider spironolactone as preferred anti-androgen

Seizure disorders

Consider referral to neurology, consult with a pharmacist re: possible estrogen interaction with anticonvulsant medication

History of benign intracranial hypertension

Consider referral to neurology/neurosurgery

Endocrine

Precautions in red impart moderate to high risk of an adverse outcome without risk mitigation. For more information on metabolic risk factors and hyperprolactinemia/prolactinoma, consult the Guidelines.

Risk Factors
How to Minimize Risks

Hyperprolactinemia

Determine etiology and manage as indicated, if prolactin >80mcg/L or symptomatic – rule out prolactinoma, refer to endocrinology as needed, consider spironolactone as preferred anti-androgen

Marked hypertriglyceridemia

Identify and address barriers to optimal lipid control, refer to dietician, minimize alcohol consumption, consider anti-lipemic pharmacologic therapy, consider endocrinology referral, use transdermal route of administration

Uncontrolled diabetes

Identify and address barriers to optimal glycemic control, refer to dietitian, encourage lifestyle modification, initiate antiglycemic agent(s) per national guidelines, consider cardiac stress test, consider transdermal route of administration

Metabolic syndrome

Dietary and medical management of component disorders, consider cardiac stress test, consider transdermal route of administration

Cardiovascular

Precautions in red impart moderate to high risk of an adverse outcome without risk mitigation. For more information on cardiovascular disease and related metabolic risk factors, consult the Guidelines.

Risk Factors
How to Minimize Risks

Stable ischemic cardiovascular disease

Consider referral to cardiology, ensure optimal medical (including prophylactic anti-platelet agent(s) if indicated per national guidelines) and/or surgical management as indicated, risk factor optimization, use transdermal route of administration +/- lower dose, consider spironolactone as preferred anti-androgen

Other cardiac diseases

Consider referral to cardiology

Uncontrolled high blood pressure

Identify and address barriers to optimal BP control, use spironolactone as anti-androgen, add additional antihypertensives as needed (avoid ACEs/ARBs with spironolactone), consider cardiac stress test, consider transdermal route of administration

Hepatic

For more information on liver/gallbladder effects, consult the Guidelines.

Risk Factors
How to Minimize Risks

Hepatic dysfunction

Dependent on etiology, e.g., minimize alcohol consumption, weight loss in NAFLD, consider referral to hepatology/GI, use transdermal, sublingual, or injectable route of administration, consider spironolactone as preferred anti-androgen

Hepatitis C

Screen patients who are at risk and treat as per current national guidelines. Keep in mind: Infection is not a contraindication to hormone therapy nor is hormone therapy a contraindication to treatment.

Oncologic

For more information on breast/chest cancer, consult the Guidelines.

Risk Factors
How to Minimize Risks

Strong family history of breast cancer

Refer to genetics/familial breast cancer program for further risk stratification and genetic testing as indicated

Prior history of estrogen-sensitive cancer

Refer to oncology

Hematologic

Precautions in red impart moderate to high risk of an adverse outcome without risk mitigation. For more information on venous thromboembolism, consult the Guidelines.

Risk Factors
How to Minimize Risks

Personal or family history of porphyria (rare)

Consider referral to porphyria clinic or internist with experience in porphyria

Hypercoagulable state or personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE)

Identify and minimize existent risk factors, prophylactic anti-platelet agent(s) if indicated per current national guidelines, consider referral to hematology/thrombosis clinic, use transdermal route of administration +/- lower dose, consider spironolactone as preferred anti-androgen

Strong family history of abnormal clotting

Rule out genetic clotting disorder, consider transdermal route of administration, consider spironolactone as preferred anti-androgen

Respiratory

Risk Factors
How to Minimize Risks

Smoker

Encourage and support smoking cessation, consider referral to smoking cessation program/offer NRT and/or bupropion/varenicline, or negotiate a decrease in smoking, consider cardiac stress test, use transdermal route of administration +/- lower dose, consider spironolactone as preferred anti-androgen, consider low-dose ASA prophylaxis

Immunologic

For more information on HIV, consult the Guidelines.

Risk Factors
How to Minimize Risks

Autoimmune conditions (e.g. RA, MS, IBD)

Start low dose, titrate slowly in collaboration with any involved specialists

HIV

Screen patients who are at risk and treat as per current national guidelines, use caution with concomitant use of spironolactone and septra (for prophylaxis of opportunistic infections) due to risk of severe hyperkalemia, pay particular attention to CVD and osteoporosis risk reduction, consider use of PrEP in HIV negative patients who are at risk

Monitoring Strategies

Standard monitoring of a feminizing regimen should be employed at baseline, and at 3, 6, and 12 months following initiation (creatinine and electrolytes should be checked 4-6 weeks after initiation or dose increase of spironolactone). Some providers prefer to see patients monthly until an effective dose is established. Follow up visits should include a functional inquiry, targeted physical exam, bloodwork, and health promotion/disease prevention counselling as indicated.

Dose titration of anti-androgen and estrogen may be performed over the course of 3-6 months or more and will depend on patient goals, physical response, measured serum hormone levels, and other lab results.

Titration Example

  • Starting dose: Initiate therapy with 1 mg oral estradiol and 50 mg of spironolactone daily;
  • At 1 month: Check creatinine and electrolytes at one month and, barring any concerns, increase estradiol to 2 mg and spironolactone to 50 mg twice daily;
  • At 3 months: Following three-month bloodwork and check-in, increase estradiol to 3 mg daily and spironolactone to 75 mg twice daily; and
  • Continue titration as needed until maintenance dose is achieved.

Hormone levels for those seeking a more androgynous appearance may intentionally be mid-range between male and female norms. For many transfeminine patients, the goal will be to achieve the suppression of testosterone into the female range (see Appendix J). Be mindful that patients may have clinically relevant results without total suppression of testosterone because of of peripheral androgen blockade, which is not measured.

In the vast majority of cases, the measurement of total testosterone is adequate to assess the degree of androgen suppression. Measurements and calculated estimates of free testosterone are imprecise and generally don’t add value.

Serum estradiol levels should also be monitored. Anecdotally, we have found that most patients reach considerable feminization at estradiol levels between 200-500 pmol/L.

When interpreting lab results, clinical effects are the goal of therapy, not specific lab values. Reference ranges will refer to the sex assigned at birth if the sex marker associated with the patient’s health card has not been changed. As reference ranges vary between laboratories, always refer to the ranges from the specific laboratory (often available online or by request). See Appendix J: Reference Ranges (Lifelabs).

Spironolactone (Without Estrogen)

Parameter
Baselinea
3-6 months

12 months

History

Screen for contraindications/drug interactions

Side effects (polyuria, orthostasis), desired effects

Side effects (polyuria, orthostasis), desired effects

PE

BP, +/- breast inspectionb (baseline)

BP, +/- breast inspectionb (baseline)

BP, +/- breast inspectionb (baseline)

Key Labs

Cr, lytes, total testosterone

Cr, lytes, total testosterone

Cr, lytes, total testosterone

Cyproterone (Without Estrogen)

Parameter
Baselinea
3 -6 months

12 months

History

Screen for contraindications/drug interactions

Side effects (depression, low energy), desired effects

Side effects (depression, low energy), desired effects

PE

Wt, BP, +/- breast inspectionb

Wt, BP, abdominal exam

Wt, BP, abdominal exam

Key Labs

CBC, ALT, Cr, lytes, total testosterone

CBCc, ALT, total testosterone, Cr, lytes

CBCc, ALT, total testosterone, fasting glucose or Hba1c, lipid profile, (+/- Cr, lytesd)

a) If not done in the preceding 3 months
b) Breast inspection at baseline with attention to Tanner stage (+/- measurement), for patients who may have interest in OHIP-covered breast augmentation
c) Red blood cell parameters can be expected to decrease with androgen blockade, female reference ranges for lower limits of normal should be used
d) Necessary only if risks/concerns identified
NB: Additional parameters required as per guidelines with estrogen; pre-existing conditions or risk factors may require earlier/more frequent monitoring of specific parameters

Note: Prolonged use of an androgen blocker without estrogen should prompt risk mitigation and monitoring for loss of bone mineral density. Annual screening for symptoms of meningioma is recommended with prolonged use (>2 years) of cyproterone.

See the table below for a summary of monitoring for transfeminine patients at baseline and at 3, 6, and 12 months after starting hormone therapy. See the Planning Period Checklist for a complete list of baseline monitoring. Note that some providers prefer to see patients monthly until an effective dose is established.

Baseline
3, 6, and 12 months

Review

  • Hormone contraindications and precautions
  • Previous records
  • Mental health
  • Lifestyle counselling
  • Psychosocial
  • Bone health
  • Health maintenance
  • Hormone effects
  • Spontaneous erections
  • Mental health
  • Lifestyle counselling
  • Psychosocial
  • Bone health

Examinations

Focused physical exam: measure BP, height, weight, +/- breast inspection/measurement(s)*

Measure BP, weight, +/- breast inspection/measurement(s) at 12 months*

Immunizations

Consider HPV, Hep A, B, and routine vaccinations as indicated

Other

See Appendix D – Preventive Care Checklist for Transfeminine Patients

*For patients who may have interest in OHIP-covered breast augmentation surgery, breast inspection at baseline and 12 months with particular attention to Tanner stage. Chest circumference at fullest part of the breast and areolar diameter may be helpful in determining the presence or absence of breast growth.

Baseline
3 months

6 months

12 months

Yearly

Per cis-patient guidelines or provider discretion

CBCa

✔

✔
(if on cyproterone)

✔
(if on cyproterone)

✔
(if on cyproterone)

✔
(if on cyproterone)

ALTb

✔

✔
(if on cyproterone)

✔
(if on cyproterone)

✔

✔

✔

Creatinine/Lytesc

✔

✔
(if on spironolactone)

✔
(if on spironolactone)

✔

✔
(if on spironolactone)

HbA1c or Fasting Glucose

✔

✔

✔

Lipid profile

✔

✔

✔

Total testosterone

✔

✔

✔

✔

✔

Estradiol

✔

✔

✔

✔

✔

Prolactind

✔

✔
(if on cyproterone)

✔
(if on cyproterone)

✔

Other

Hep B, C

Consider HIV, syphillis, and other STI screenings

a) Baseline for all and regularly with cyproterone, otherwise repeat once at 6-12 months then as needed. For Hb/Hct use female reference for lower limit of normal and male reference for upper limit of normal.
b) Baseline for all and regularly with cyproterone, otherwise repeat once at 6-12 months then as needed.
c) Cr/lytes should be monitored at each visit with spironolactone (including 4-6 weeks after starting and after any dose changes), but is only required at baseline and then once between 6-12 months with cyproterone unless risk factors or concerns re: renal disease are present; use male reference range for upper limit of normal for Cr
.
d) Prolactin should be monitored at least yearly with the use of cyproterone, and more frequently if elevation noted.

Long-Term Preventive Care

Transfeminine patients maintained on feminizing hormone therapy have unique preventive care needs. Their long-term care should involve at least annual preventive care visits. A Preventive Care Checklist with accompanying explanations for trans-specific recommendations is available below.

Ensuring Patient Comfort in Clinical Encounters

Physical exams involving intimate body parts are uncomfortable for anyone, but trans and non-binary patients may need a slightly different approach in some areas of primary care—including disease prevention and screening. Reflecting on our approach to these encounters helps provide a more comfortable, gender-affirming experience.

Provide Care Based on Organs Present

It is best to base routine screening on the presence or absence of body parts. Refrain from calling body parts ‘male’ or ‘female’. Instead use non-gendered terms or ask the patient what they prefer to call their body parts. Organs present should receive routine preventive care.

Bones (Illustration of a pelvis)

Osteoporosis and Bone Mineral Density Screening

Indications for Bone Mineral Density (BMD) Screening

  • All patients over 65 years old
  • Patients 50-64 years old at higher risk for osteoporosis (e.g., smoking history, HIV+, high alcohol intake, body weight under 60 kg)
  • Consider before 50 years in:
    • Certain high-risk conditions such as hyperparathyroidism or malabsorption syndrome
    • Patients who have undergone orchiectomy and have been on low-dose or no hormones for any significant length of time (>2 years)
    • Patients who have been on anti-androgens or a GnRH analogue for a significant length of time (>2 years) without co-administration of exogenous estrogen
  • All transfeminine patients should ensure a daily intake of 1000 IU Vitamin D and 1200mg of calcium (total of diet + supplements)
  • Weight-bearing exercise should also be encouraged (this could include walking and low-impact aerobic exercise)

Keep in mind that there are no studies to guide the interpretation of BMD results and fracture risk in trans people, including whether to use sex assigned at birth or affirmed gender. One option is to interpret results in comparison to both cis men and cis women; frequency of BMD screening will depend on the results of the initial scan.

Breast/Chest Health (Icon of a feminine torso)

Breast/Chest Health

  • Longer duration of feminizing hormone exposure (i.e. number of years taking estrogen), family history of breast cancer, obesity (BMI >35), and the use of progestins likely increase the level of risk of breast cancer.6
  • Transfeminine patients should receive counselling around breast self-awareness as is recommended for cis women.
  • Annual clinical breast examination as part of routine breast cancer screening is of questionable utility, but may be useful in transfeminine patients to assess the degree of breast development or to assess for implant complications if the patient has undergone breast augmentation.

Keep in mind, in Ontario, transfeminine patients who have changed their OHIP sex marker to “female” can be screened as part of the organized Ontario Breast Screening Program.

Use this diagram to find out whether your patient needs breast cancer screening.

Use the diagram to find out whether your client needs screening for implant rupture.

Colon Cancer Screening (Illustration of a colon)

Colon Cancer Screening

Screening guidelines for transfeminine patients are no different than for cis populations. Please follow your local screening guidelines (e.g., Cancer Care Ontario for Ontario guidelines).

Cervical Cancer Screening (Illustration of a cervix)

Cervical Cancer Screening

If the patient has not had a vaginoplasty, screening is not necessary.

If the patient has had a vaginoplasty without a neo-cervix, screening is not necessary. However, the neo-vagina should be visually inspected annually for abnormalities such as granulation tissue, active hair follicles, warts, abnormal discharge, or malignancy. Granulation tissue may be treated with silver nitrate cauterization.

If the patient has had a vaginoplasty with a neo-cervix, which is rare, screening should follow guidelines as for cis women.

Patients with a neo-cervix who are 21 to 69 years of age should be screened based on sexual activity. If not sexually active, note that those who become sexually active after age 21 should have their first Pap test within three years of doing so. If sexually active, they should receive a Pap test every three years.

Prostate Exam (Illustration of prostate)

Prostate Exam

The risk of prostate cancer is not increased by estrogen use; in fact it is reasonable to assume that the risk is significantly decreased by the associated androgen deprivation. Although rare, there have been cases of prostate cancer reported in transfeminine patients, generally occurring in those who started hormone therapy after the age of 50.7, 8 It is important to note that estrogen will lower PSA values even in the presence of prostate cancer, thus impacting its utility in this population. A reduction in the upper limit of normal for PSA to 1 ng/L can be considered in transfeminine patients with low testosterone.9 Routine PSA screening is not recommended in transfeminine patients in the absence of significant risk factors. There is little evidence to support a role for annual DRE in prostate cancer screening; however, it may be considered according to a provider’s routine practice with cis men. In patients who have undergone vaginoplasty, the prostate remains in situ and may be palpated anteriorly via digital vaginal exam in a gender affirming lithotomy position.

  1. Hembree WC, Cohen-Kettenis P, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903. doi:10.1210/jc.2017-01658
  2. Wierckx K, Gooren L, T’Sjoen G. Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med. 2014;11(5):1240–7. doi:10.1111/jsm.12487
  3. Orentreich N, Durr NP. Mammogenesis in transsexuals. J Invest Dermatol. 1974;63(1):142–6. doi:10.1111/1523-1747.ep12679317
  4. Wierckx K, Gooren L, T’Sjoen G. Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med. 2014;11(5):1240–7. doi:10.1111/jsm.12487
  5. de Blok C, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab. 2018;103(2):532–8. doi:10.1210/jc.2017-01806
  6. Feldman J, Safer J. Hormone therapy in adults: suggested revisions to the sixth version of the standards of care. Int J Transgend. 2009;11(3):146–82
  7. Gooren LJ, Giltay EJ, Bunck MC. Long term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008; 93(1):19-25
  8. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2008; 159(3):197-202
  9. Trum HW, Hoebeke P, Gooren LJ. Sex reassignment of transsexual people from a gynecologist’s and urologist’s persective. Acta Obstet Gynecol Scand 2015; 94(6):563-567